Regulation/Legislation (Wellness)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Wellness & Regulation
ASA Finds 'Irresponsible' Weight Loss Ad Difficult To Stomach
Vision Healthcare’s Sensilab pulled Facebook advertisements for its weight loss supplements after UK regulator the Advertising Standards Authority launched an investigation into whether the marketing, which featured slim models, was "irresponsible."
Studies Find Oil, Topical And Transdermal Hemp Products’ Content Inconsistent With Labeling
JAMA study found 24% of 89 topicals or transdermals labeled correctly for amounts of cannabinoid in the products; JCR study found 54% of 80 CBD oils were accurately labeled, 15% had higher levels and 31% had lower.
House Members Object To Senate Adding Supplement MPL Proposal In FDA User Fee Bill
Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.
Latest From Wellness & Legislation
Studies Find Oil, Topical And Transdermal Hemp Products’ Content Inconsistent With Labeling
JAMA study found 24% of 89 topicals or transdermals labeled correctly for amounts of cannabinoid in the products; JCR study found 54% of 80 CBD oils were accurately labeled, 15% had higher levels and 31% had lower.
House Members Object To Senate Adding Supplement MPL Proposal In FDA User Fee Bill
Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.
Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.